Category: Kevin Outterson

Clinical Trial Transparency — Antidote to Weaker Off-Label-Promotion Rules?

July 7th, 2014 in 2014, Kevin Outterson, New England Journal of Medicine, Newsmakers, OP-EDs by BU Professors, School of Law 0 comments

Kevin-Outterson-260x300New England Journal of Medicine
By Kevin Outterson, School of Law

This year promises to be an auspicious period for some long-running battles over the dissemination of biomedical research. Some companies seeking more freedom to promote their products have bristled at recent guidance documents from the Food and Drug Administration (FDA) regarding promotion of drugs and devices for off-label uses, claiming that they violate the First Amendment…

View full article by expert Kevin Outterson

Antibiotic resistance

July 2nd, 2014 in 2014, BBC, Kevin Outterson, Newsmakers, School of Law 0 comments

Kevin-Outterson-260x300BBC News
Kevin Outterson, School of Law

Kevin Outterson discusses the antibiotic business model.

View video of expert Kevin Outterson

Kevin Outterson to speak at Global Technology Community Summit

June 25th, 2014 in 2014, Kevin Outterson, Newsmakers, Professor Extras, School of Law, Twitter 0 comments

View tweet on Kevin Outterson
(Bio of Outterson)

Screen shot 2014-06-25 at 2.27.12 PM

Cholera cure or basketball: What’s the best way to spend $2 billion?

June 2nd, 2014 in 2014, Kevin Outterson, Los Angeles Times, Newsmakers, School of Law 0 comments

Kevin-Outterson-260x300Los Angeles Times
Kevin Outterson, School of Law

Kevin Outterson of Boston University’s School of Public Health raises the question, a little mischievously, of whether Steve Ballmer’s $2 billion is really being put to the greatest possible social use…

Expert quote:

“Cholera is a disease of poverty, linked to poor sanitation and a lack of potable water. Establishment of an adequate sanitation and potable-water system is the most definitive way to prevent and limit its spread.”

View full article

Superbug crisis: Global push to save antibiotics begins

May 20th, 2014 in 2014, Kevin Outterson, New Scientist, Newsmakers, School of Law 0 comments

Kevin-Outterson-260x300New Scientist
Kevin Outterson, School of Law

“A post-antibiotics era in which common infections and minor injuries can kill, far from being an apocalyptic fantasy, is instead a very real possibility for the 21st century.” That was the warning last month from the World Health Organization in its first global report on the growing ability of bacteria to resist antibiotics…

View full article quoting expert Kevin Outterson

Why make new antibiotics when no one is paying for them?

May 1st, 2014 in 2014, Kevin Outterson, Newsmakers, School of Law 0 comments

Kevin-Outterson-260x300Quartz
Kevin Outterson, School of Law

Bacteria are evolving into drug-resistant superbugs, and the number of effective antibiotics continues to dwindle…

View full article quoting expert Kevin Outterson

Report urges controversial ‘delinkage’ to foster new antibiotics

April 9th, 2014 in 2014, Kevin Outterson, Nature, Newsmakers, School of Law 0 comments

Kevin-Outterson-260x300Nature
Kevin Outterson, School of Law

It is conceivable that the day may come when a pandemic bacterial strain emerges with resistance to all of the drugs currently available in our medical arsenal. Given this possible threat, a leading UK think tank has released a report calling for a radical new business model to kickstart the development of new antibiotics…

Expert quote:

“From society’s perspective, we want antibiotics to be available and used appropriately and from a company’s perspective, they want a credible commitment that when they commit funds to antibiotic research and development, in ten years’ time the money will be there.”

View full article

FDA to expedite drug OKs

February 22nd, 2014 in 2014, Boston Herald, Kevin Outterson, Newsmakers, School of Law 0 comments

Kevin-Outterson-260x300Boston Herald
Kevin Outterson, School of Law

The Food and Drug Administration wants to change the way it approves over-the-counter drugs, a move that could dramatically reduce the time it takes for thousands of products to reach store shelves…

Expert quote:

“The monograph system is a very clunky way to regulate thousands of products. It punishes companies that do ask to add or change an ingredient in their product by subjecting them to a process that can take years.”

View full article

The Search For New Antibiotics

February 17th, 2014 in 2014, Kevin Outterson, Newsmakers, NPR, School of Law 0 comments

Kevin-Outterson-260x300NPR “Here & Now”
Kevin Outterson, School of Law

Two drug companies, Roche Holding and GlaxoSmithKline, have announced they’ll ramp up research into antibiotics…

Listen to audio of expert Kevin Outterson

Political gridlock empowers US justices

June 30th, 2013 in 2013, Financial Times, Kevin Outterson, Newsmakers, School of Law 0 comments

outterson_white-new_65wFinancial Times (subscription required)
Kevin Outterson, School of Law

Antonin Scalia, the US Supreme Court’s most colourful conservative, issued a furious dissent from the bench on its ruling advancing gay rights this week, saying that his fellow justices had “an exalted notion” of their role in American democracy…

Expert quote:

“But in the current climate, what is the chance that Congress will be able to intervene? Virtually nil.”

View full article